120 likes | 135 Views
According to the latest research report by IMARC Group, The global macular degeneration treatment market size reached US$ 8.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 12.9 Billion by 2028, exhibiting a growth rate (CAGR) of 6.2% during 2023-2028. <br><br>More Info:- https://www.imarcgroup.com/macular-degeneration-treatment-market
E N D
Global Macular Degeneration Treatment Market Research and Forecast Report 2023-2028 Author: Elena Anderson, Marketing Manager | Copyright © IMARC Service Pvt Ltd. All Rights Reserved IMARC Group © 2019 IMARC All Rights Reserved
Report DescriptionAbout IMARC Group The International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value challenges, and transform their businesses. opportunities, address their most critical IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.
Report Description and Highlights Report Description Global Macular Degeneration Treatment Market Research Report: The latest report by IMARC, titled “Macular Degeneration Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028” finds that the global macular degeneration treatment market size reached US$ 8.9 Billion in 2022. Macular degeneration is a neurodegenerative eye disorder caused by deterioration of the macula, the part of the retina that controls sharp, straight-ahead vision. It leads to blurred or complete vision loss in the center of the visual field. The condition is generally characterized by blind or blurry spots in the field of vision, visual distortions, and the inability to see in low light conditions. It can be treated by various therapeutic techniques, such as anti-angiogenic drugs, photodynamic laser therapies, contact lenses, and transitional lenses. In recent years, macular degeneration treatment has gained immense traction across the globe as timely treatment can help improve vision and reduce the risks of developing chronic or permanent blindness. Request market/requestsample Free Sample Report: https://www.imarcgroup.com/macular-degeneration-treatment-
Report Description and Highlights Report Description Global Macular Degeneration Treatment Market Trends: The rising incidences of retinal disorders and the surging awareness regarding available treatment options among the masses represent the primary factors driving the market growth. Besides this, since macular degeneration usually affects older adults, the expanding geriatric population is another major growth-inducing factor. Additionally, there has been a widespread prevalence of obesity and cardiovascular diseases (CVDs) due to sedentary lifestyles, changing dietary patterns, and unhealthy habits like smoking. In line with this, prolonged screen time owing to the growing usage of smartphones, laptops, and television is contributing to the development of eye conditions, which has augmented the demand for macular degeneration treatment. Furthermore, the leading players are extensively investing in research and development (R&D) activities to develop innovative and effective drugs. Along with this, the introduction of retinal gene therapies that involve injecting adeno-associated virus (AAV) into the body to prevent the growth of abnormal blood vessels has propelled the market growth. Other factors, including the rising popularity of biosimilars, increasing approvals of novel drugs, favorable government initiatives, improving healthcare infrastructure, and technological advancements, are also providing a positive thrust to the market growth. Looking forward, IMARC Group expects the market value to reach US$ 12.9 Billion by 2028, growing at a CAGR of 6.2% during the forecast period (2023-2028). Looking forward, the market value is projected to reach a strong growth during the forecast period (2023-2028).
Report Description and Highlights Report Description Market Summary: Breakup by Type: • Dry Age-related Macular Degeneration • Wet Age-related Macular Degeneration Breakup by Stage of Disease: • Early Stage • Intermediate Stage • Late Stage Breakup by Route of Administration: • Intravenous Route • Intravitreal Route Breakup by End User: • Hospitals • Ambulatory Surgical Center • Others
Report Description and Highlights Report Description Breakup by Region: • North America • United States • Canada • Asia-Pacific • China • Japan • India • South Korea • Australia • Indonesia • Others • Europe • Germany • France • United Kingdom • Italy • Spain • Russia
Report Description and Highlights Report Description • Others • Latin America • Brazil • Mexico • Others • Middle East and Africa
Report Description and Highlights Report Description Competitive Landscape with Key Players: • • • • • • • • • • • • Aerie Pharmaceuticals Inc Bausch Health Companies Inc. Bayer AG F. Hoffmann-La Roche Ltd Iveric Bio Inc. Novartis AG Panoptica Pfizer Inc. Phio Pharmaceuticals Regeneron Pharmaceuticals Inc. Regenxbio Inc. Santen Pharmaceutical Co. Ltd. View Full Report with TOC & List of Figure: https://www.imarcgroup.com/macular-degeneration- treatment-market
We are the trusted business partners to the world's leading corporates, governments, and institutions Partial List of Clients A partial List of our Clients
We are the trusted business partners to the world's leading corporates, governments, and institutions Partial List of Clients A partial List of our Clients
Report Description and Highlights Report Description © 2019 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC). Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication. IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.
Contact Us FOR MORE DETAILS Visit us at : https://www.imarcgroup.com Stay With Us: TELEPHONE: +1-631-791-1145 E-MAIL: sales@imarcgroup.com